Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
04 Settembre 2024 - 2:00PM
Business Wire
Collaboration stands to advance novel
therapeutic applications across multiple neurologic conditions
Charles River Laboratories International, Inc. (NYSE: CRL) and
Insightec, a global healthcare company dedicated to using focused
ultrasound to transform patient care, today announced the launch of
a five-year strategic collaboration to provide Charles River’s
clients access to a comprehensive global service and technology
platform for the application of focused ultrasound (FUS) for drug
discovery and preclinical development of therapeutics in
neuroscience. Insightec’s novel low-frequency ultrasound platform
non-invasively disrupts the blood-brain barrier, enabling drugs to
be delivered to targeted brain areas. The procedure has generated
positive clinical evidence across several neurological diseases,
including Parkinson’s disease, Alzheimer’s disease, and oncology
indications, and holds promise for increasing efficacy of
neurological drugs, to impact better health and outcomes for
patients in the future.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240904804676/en/
“Our collaboration with Insightec represents a significant step
forward in advancing neuroscience research,” said Professor Julie
Frearson, PhD, Senior Vice President and Chief Scientific Officer
at Charles River. “As we look toward the future of drug discovery,
we recognize that technology will be a cornerstone of innovation.
The integration of focused ultrasound technology into our
preclinical services will enhance the precision and effectiveness
of therapeutic delivery strategies, allowing us to refine our use
of research models and support the discovery of novel
medicines.”
Collaboration in Neuroscience
Designed to meet the increasing demand to quickly advance
therapeutic development and delivery of genetic medicines,
biologics, and immunotherapies in multiple Good Laboratory Practice
(GLP) preclinical models in neuroscience, the collaboration
provides powerful CNS drug delivery for multiple drug types.
Insightec’s low-intensity focused ultrasound along with microbubble
resonators noninvasively modulate the blood-brain barrier, allowing
precise therapeutic delivery of a variety of drugs, including
delivery to deep brain structures. Insightec’s technology has the
potential to revolutionize central nervous system (CNS) delivery
for genetic medicines, biologics, and immunotherapies across a
variety of tough-to-treat CNS diseases, including ones associated
with neurodegeneration, neurodevelopment, and neuro-oncology.
“This partnership will not only expand the application of our
low-frequency focused ultrasound technology, but also accelerate
the development of groundbreaking therapies for neurological
conditions,” said Arjun Desai, M.D., Chief Strategic Innovation
Officer of Insightec. “By combining our expertise, we aim to
revolutionize the way next generation therapeutics are delivered
and actuated in the brain, ultimately improving the lives of
millions globally.”
About Insightec
Insightec is a global healthcare company creating the next
generation of patient care by realizing the therapeutic power of
focused ultrasound. The company’s Exablate Neuro platform focuses
sound waves, safely guided by MRI, to provide tremor treatment to
patients with medication-refractory essential tremor and
Parkinson's disease. Both clinical and pre-clinical research for
future applications in the neuroscience space is underway in
partnership with leading academic and medical institutions.
Insightec is headquartered in Haifa, Israel, and Miami, with
offices in Dallas, Shanghai, and Tokyo.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “intend,” “will,”
“would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and
other similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
statements also include statements regarding expectations with
respect to the efficacy, effectiveness and precision of drug
products. of Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or
implied by the statements. Any forward-looking statement is based
on information available to Insightec and/or Charles River as of
the date of the statement. All written or oral forward-looking
statements attributable to Insightec and/or Charles River are
qualified by this caution. Insightec and/or Charles River does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Insightec’s
and/or Charles River’s expectations.
“Exablate,” and “Exablate Neuro,” as well as the “Insightec”
logo, whether standing alone or in connection with the word
“Insightec,” are protected trademarks of Insightec.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240904804676/en/
Insightec Media Contact: G&S Business Communications
for Insightec Marjani Williams mwilliams@gscommunications.com (312)
648-6700, ext.2108
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations 781.222.6455
todd.spencer@crl.com
Charles River Media Contact: Amy Cianciaruso Corporate
Vice President, Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Grafico Azioni Charles River Laboratories (NYSE:CRL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Charles River Laboratories (NYSE:CRL)
Storico
Da Dic 2023 a Dic 2024
